NuroKor BioElectronic Technologies: Led by evidence, driven for change
NuroKor is dedicated to the development of bioelectronic technologies. We’re evidence-led, research-driven, with proven healthcare applications and our devices are CE-marked and FDA-cleared to deliver personalised treatment for certain conditions.
In this blog series, we’ll be addressing how we think about NuroKor in the context of healthcare and clinicians, shining a light on the potential impact of electrotherapy in the care of people living with health challenges.
At NuroKor, we believe in bioelectric technology, but before we consider its applications, first, we review the evidence.
We are an evidence-led bioelectric technology company. But we don’t blindly push the tech - we’re guided by the evidence behind it.
We regularly search the literature, and so far we’ve read more than 500 studies (many of them randomised controlled trials and meta-analyses - the highest levels of evidence) on the applications of bioelectric medicine. Looking at how effective it is at treating conditions like pain, muscle weakness in the elderly, poor wound healing and more. We’re consistently seeking out the latest clinical studies into the three bioelectrical stimulation technologies that underpin NuroKor, as well as specific bioelectrical formulation studies. We then assess the weight and quality of the evidence to evolve our understanding of how bioelectric technologies can best provide support to people experiencing a wide range of health challenges.
Current evidence suggests that electrotherapy administration can significantly contribute to:
- Relieving postoperative pain and therefore decreasing the number of pharmacological analgesics used (14 studies, the majority RCTs)
- Promoting wound healing and helping to decrease inflammation and pain (10 studies, including RCT)
- Preventing muscle atrophy and loss of function, and improving fitness in ageing population
- Relieving pain and improving functionality in patients with neck or back pain (11 studies, including various RCTs)
In the case of electrotherapy, studies generally use a single waveform and single frequency (a single formulation) on a population to determine how effective it is at treating a certain condition. In this context, it is important to remember that devices like NuroKor’s are capable of delivering multiple formulations and as yet, multi-frequency studies are not common-place, so the full potential of this type of technology is yet to be realised through clinical evidence.
At NuroKor, this excites us. We’re at the very beginning of brand new bioelectric technologies that have the potential to make real change in the lives of so many. In our next article, we’ll be explaining our latest mission to advance bioelectric technology through our own clinical studies…
Founded in 2018, NuroKor is a company committed to the development of bioelectronic technologies. NuroKor develops and formulates programmable bioelectronic software for clinical and therapeutic applications, in a range of easy to use, wearable devices. It provides the highest-quality products, delivering personalised pain relief and recovery support and rehabilitation to patients.